Anti-human CD19 antibodies
The present disclosure relates to antibodies that bind human CD19 (“anti-human CD19 antibodies” or “anti-human CD19 antibodies”), compositions comprising such anti-human CD19 antibodies, and methods of using such anti-human CD19 antibodies.
1. An antibody that binds human CD19, wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein
the HCDR1 comprises SEQ ID NO: 29,
the HCDR2 comprises SEQ ID NO: 30,
the HCDR3 comprises SEQ ID NO: 31,
the LCDR1 comprises SEQ ID NO: 32,
the LCDR2 comprises SEQ ID NO: 33, and
the LCDR3 comprises SEQ ID NO: 34.
2. The antibody of claim 1 , wherein the VH comprises SEQ ID NO: 37 and the VL comprises SEQ ID NO: 41.
3. The antibody of claim 1 , wherein the antibody comprises a heavy chain (HC) comprising SEQ ID NO: 35 and a light chain (LC) comprising SEQ ID NO: 39.
4. The antibody of claim 1 , wherein the antibody comprises a HC comprising SEQ ID NO: 52 and a LC comprising SEQ ID NO: 39.
5. An antibody that binds human CD19, wherein the antibody comprises a VH and a VL, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, wherein
the HCDR1 comprises SEQ ID NO: 29,
the HCDR2 comprises SEQ ID NO: 30,
the HCDR3 comprises SEQ ID NO: 31,
the LCDR1 comprises SEQ ID NO: 43,
the LCDR2 comprises SEQ ID NO: 44, and
the LCDR3 comprises SEQ ID NO: 45.
6. The antibody of claim 5 , wherein the VH comprises SEQ ID NO: 37 and the VL comprises SEQ ID NO: 48.
7. The antibody of claim 5 , wherein the antibody comprises a HC comprising SEQ ID NO: 35 and a LC comprising SEQ ID NO: 46.
8. The antibody of claim 5 , wherein the antibody comprises a HC comprising SEQ ID NO: 52 and a LC comprising SEQ ID NO: 46.
9. An antibody that binds human CD19, wherein the antibody comprises a VH and a VL, wherein the VH comprises HCDR1, HCDR2, and HCDR3, and the VL comprises LCDR1, LCDR2, and LCDR3, wherein
the HCDR1 comprises SEQ ID NO: 15,
the HCDR2 comprises SEQ ID NO: 16,
the HCDR3 comprises SEQ ID NO: 17,
the LCDR1 comprises SEQ ID NO: 18,
the LCDR2 comprises SEQ ID NO: 19, and
the LCDR3 comprises SEQ ID NO: 20.
10. The antibody of claim 9 , wherein the VH comprises SEQ ID NO: 23 and the VL comprises SEQ ID NO: 27.
11. The antibody of claim 9 , wherein the antibody comprises a HC comprising SEQ ID NO: 21 and a LC comprising SEQ ID NO: 25.
12. The antibody of claim 9 , wherein the antibody comprises a HC comprising SEQ ID NO: 54 and a LC comprising SEQ ID NO: 25.
13. The antibody of claim 1 , wherein the antibody is a non-depleting antibody.
14. The antibody of claim 5 , wherein the antibody is a non-depleting antibody.
15. The antibody of claim 9 , wherein the antibody is a non-depleting antibody.
16. A nucleic acid comprising a sequence encoding SEQ ID NO: 35, 52, 39, 46, 21, 54, or 25.
17. A vector comprising the nucleic acid of claim 16 .
18. The vector of claim 17 , wherein the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second nucleic acid sequence encoding SEQ ID NO: 39 or 46.
19. The vector of claim 17 , wherein the vector comprises a first nucleic acid sequence encoding SEQ ID NO: 21 or 54, and a second nucleic acid sequence encoding SEQ ID NO: 25.
20. A composition comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 39 or 46.
21. A composition comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 21 or 54, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 25.
22. A cell comprising the vector of claim 17 .
23. A cell comprising the vector of claim 18 .
24. A cell comprising the vector of claim 19 .
25. A cell comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 35 or 52, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 39 or 46.
26. A cell comprising a first vector comprising a nucleic acid sequence encoding SEQ ID NO: 21 or 54, and a second vector comprising a nucleic acid sequence encoding SEQ ID NO: 25.
27. The cell of claim 22 , wherein the cell is a mammalian cell.
28. The cell of claim 23 , wherein the cell is a mammalian cell.
29. The cell of claim 24 , wherein the cell is a mammalian cell.
30. The cell of claim 25 , wherein the cell is a mammalian cell.
31. The cell of claim 26 , wherein the cell is a mammalian cell.
32. A process of producing an antibody comprising culturing the cell of claim 23 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.
33. A process of producing an antibody comprising culturing the cell of claim 24 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.
34. A process of producing an antibody comprising culturing the cell of claim 25 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.
35. A process of producing an antibody comprising culturing the cell of claim 26 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.
36. An antibody produced by the process of claim 32 .
37. An antibody produced by the process of claim 33 .
38. An antibody produced by the process of claim 34 .
39. An antibody produced by the process of claim 35 .
40. A pharmaceutical composition comprising the antibody of claim 1 , and a pharmaceutically acceptable excipient, diluent or carrier.
41. A pharmaceutical composition comprising the antibody of claim 5 , and a pharmaceutically acceptable excipient, diluent or carrier.
42. A pharmaceutical composition comprising the antibody of claim 9 , and a pharmaceutically acceptable excipient, diluent or carrier.
43. A method of treating a B cell associated disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of claim 1 .
44. The method of claim 43 , wherein the B cell associated disorder is an autoimmune disease.
45. The method of claim 43 , wherein the B cell associated disorder is selected from systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome, idiopathic thrombocytopenia purpura, Type 1 diabetes, pemphigus vulgaris, meuromyelitis optica, ANCA vasculitis, or myasthenia gravis.
46. A method of treating a B cell associated disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of claim 5 .
47. The method of claim 46 , wherein the B cell associated disorder is an autoimmune disease.
48. The method of claim 46 , wherein the B cell associated disorder is selected from systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome, idiopathic thrombocytopenia purpura, Type 1 diabetes, pemphigus vulgaris, meuromyelitis optica, ANCA vasculitis, or myasthenia gravis.
49. A method of treating a B cell associated disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of claim 9 .
50. The method of claim 49 , wherein the B cell associated disorder is an autoimmune disease.
51. The method of claim 49 , wherein the B cell associated disorder is selected from systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, Sjogren's syndrome, idiopathic thrombocytopenia purpura, Type 1 diabetes, pemphigus vulgaris, meuromyelitis optica, ANCA vasculitis, or myasthenia gravis.